A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 8 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This publication is about entering into non-exclusive discount contracts according to § 130a Abs. 8 SGB V for finished medicines containing the active ingredient Abaloparatide (ATC: H05AA04) as part of an "open-house model". Under uniform contract conditions and a standardized access procedure, all
The health insurance funds (whether HEK and/or hkk participate in each lot is determined by the designation of the respective lot) aim to establish discount contracts with all suitable pharmaceutical companies according to § 130a Abs. 8 SGB V for the active ingredients, combinations of active ingred
This contract opportunity involves the establishment of discount contracts for various active ingredients under the Open-House procedure, as per § 130a Abs. 8 SGB V. All eligible and interested pharmaceutical companies or consortia are invited to enter into discount contracts under uniform terms and
This contract opportunity is for the procurement of endovascular devices specifically designed for mechanical thrombectomy procedures. The buyer, CH GPE HOSP DE LA ROCHELLE RE AUNIS, is seeking suppliers to provide two lots of these medical devices. The aim is to enhance healthcare services in the r
The KKH (Kaufmännische Krankenkasse) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process allows all eligible and interested pharmaceutical companies or groups to
The Kaufmännische Krankenkasse (KKH) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the active ingredients specified in this contract, following the Open-House procedure. This process allows all eligible and interested pharmaceutical companies or c
This contract opportunity involves the establishment of discount contracts for various pharmaceutical substances under the Open-House procedure, as per § 130a Abs. 8 SGB V. All eligible and interested pharmaceutical companies or consortia are invited to enter into discount contracts for the followin
The Techniker Krankenkasse (TK) aims to establish discount contracts with all suitable pharmaceutical companies for the combination of active ingredients Formoterol/Glycopyrronium/Budesonide, in accordance with § 130a Abs. 8 SGB V. The contract will be concluded under TK's Open House Original proced
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abiraterone (500 mg, 90 tablets) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from December 1, 2025, to November 30, 2027. The process will involve formal procuremen
The German health insurance fund DAK-Gesundheit is seeking suppliers for a non-exclusive discount agreement for the drug Tocilizumab (specifically pre-filled syringes and pens) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from December 1, 2025, to November 30, 2027.
